pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
BioSpace·Sep 14·1 min read
save

Novo drops Nordisk from name, rebrands as Novo with new bull logo

Sep 14, 2026·read at BioSpace ↗Neutral

Novo Nordisk announced it will drop the "Nordisk" part of its name, rebranding simply as Novo and rotating the iconic Apis bull in its logo to signal a new direction.

CEO Mike Maziar Doustdar said the brand and culture changes are strategically important but the company’s purpose of improving lives remains unchanged, emphasizing more responsive and everyday‑fit healthcare.

Analysts responded with tentative approval, noting the rebrand could be a prelude to a broader strategic shift as Novo seeks to regain footing in the competitive GLP‑1 market against rivals such as Eli Lilly.

Novo plans a capital markets day on September 21 to detail its future strategy and how the rebrand fits into its longer‑term plans.

source

This writeup was produced by pharmadog from original reporting by BioSpace.

Original headline: “Novo drops ‘Nordisk’ moniker, turns bull toward future in corporate rebrand”

read at BioSpace ↗
819 words · retrieved Sep 14
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
NOVO29Novo Nordisk Inc8LILLY5ELI LILLY CO3PATH3CATALENT2Ultragenyx Pharmaceutical Inc.
drugs
Obesity5OzempicRare DiseaseWegovyWegovy Pill
topics
Obesity6GLP-1 receptor3Small Molecule2Type 2 Diabetes2ApprovalCardiologyHypertensionPulmonologyRare Disease

related stories

  • Sep 23Novo’s turnaround plan, weight loss wins, Ultragenyx’s Sanfilippo approval, IPO blitzBioSpace
  • Aug 28Lilly joins Novo in cardiovascular space after FDA nod for GLP-1/GIP agonist MounjaroBioSpace
  • Jun 2910 clinical trials to watch in the second half of 2026BioPharma Dive
  • Oct 19Should amylin have been obesity therapeutics’ primary target from the start?BioSpace
  • Aug 28STAT+: Pharmalittle: We’re reading about an AstraZeneca trial failure, a ‘monstrous’ conflict of interest, and moreSTAT